A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Summary

This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.

Timeline

Start

2023-11-14

Primary completion

2026-04-16

Completion

2026-04-16

Outcome

Outcome not reported

Stopped (Business): “The trial was terminated for strategic reasons. The decision was not based on any safety concerns”

Drugs

Indications